Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by alixx11on Jan 16, 2013 9:55am
163 Views
Post# 20844245

RE: RE: NOX BEGINS PROGRAM ON MARBAN BLOCK

RE: RE: NOX BEGINS PROGRAM ON MARBAN BLOCK

I see the other side of the coin. I'm more pessimistic :

"In light of Aurizon's ongoing review of the Phase II data, Niogold has agreed to fund the exploration program at this time. The parties have further agreed, however, that upon Aurizon's decision to proceed with the Phase III program, Aurizon will immediately reimburse Niogold for the costs of the exploration program"

What I read into this statement is that Aurizon, as of January 2013, is STILL unsure about the value of phase 2 results after months of reviewing. Niogold may be sensing they'll pull out, and that they better start generating some results on their own in order to attract another partner soon...

IMHO, but I don't really like this news.

<< Previous
Bullboard Posts
Next >>